SAFETY AND POTENTIAL EFFECT OF INNOVATIVE CELL-BASED THERAPY USING ADIPOSE-DERIVED STROMAL VASCULAR FRACTION IN PATIENTS WITH AUTOIMMUNE XEROSTOMIA (STUDY XEROCELL)
Phase 1
- Conditions
- AUTOIMMUNE XEROSTOMIATherapeutic area: Diseases [C] - Stomatognathic Diseases [C07]
- Registration Number
- CTIS2023-505149-20-00
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method